장내미생물 (microbiome), 신약개발의 새로운 타겟

소개글

장내미생물 (microbiome), 신약개발의 새로운 타겟에 대한 보고서 자료입니다.

목차

Ⅰ. 서론

Ⅱ. 본론
2.1 Gut microbiota (장내 미생물)
2.2 장내 미생물이 host에 미치는 영향과 질병사이의 상관관계
1) 장내 미생물의 에너지 획득과 비만
2) 장내 미생물의 장 투과성 조절과 염증반응
3) 장내 미생물과 독성 대사체
2.3 장내 미생물에 영향을 주는 요소들
2.4 장내 미생물 타겟 신약개발 전략
2.4 장내 미생물 신약개발을 위해 필요한 것들

Ⅲ. 결론

Ⅳ. 참고문헌

본문내용

리바이오틱스 [prebiotics] (식품과학기술대사전, 2008.4.10., 광일문화사)
[네이버 지식백과] 프로바이오틱스 [probiotics] (시사상식사전, 박문각)
[네이버 지식백과] 대사성 질환 (한경 경제용어사전, 한국경제신문/한경닷컴 )
[네이버 지식백과] 대사성질환 [metabolic disease, 代謝性疾患, たいしゃせいしっかん] (용어해설)
http://en.wikipedia.org/wiki/Microbiome
http://navercast.naver.com/magazine_contents.nhn?rid=1377&contents_id=73643
http://biz.chosun.com/site/data/html_dir/2014/06/26/2014062602484.html
http://news.khan.co.kr/kh_news/khan_art_view.html?artid=201207052115455&code=930401
http://www.kormedi.com/news/article/1200964_2892.html
http://www.hmpdacc.org/
<표1의 참고문헌>
5. Turnbaugh, P. J. et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 10271031 (2006).
6. Ley, R. E., Turnbaugh, P. J., Klein, S. & Gordon, J. I. Microbial ecology: human gut microbes associated with obesity. Nature 444, 10221023 (2006).
58. Surawicz, C. M. et al. Prevention of antibioticassociated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 96, 981988 (1989).
59. Surawicz, C. M. et al. The search for a better treatment for recurrent Clostridium difficile disease: use of highdose vancomycin combined with Saccharomyces boulardii. Clin. Infect. Dis. 31, 10121017 (2000).
60. Cummings, J. H., Macfarlane, G. T. & Macfarlane, S. Intestinal bacteria and ulcerative colitis. Curr. Issues Intest. Microbiol. 4, 920 (2003).
61. Subramanian, S., Campbell, B. J. & Rhodes, J. M. Bacteria in the pathogenesis of inflammatory bowel disease. Curr. Opin. Infect. Dis. 19, 475484 (2006).
62. Andoh, A. & Fujiyama, Y. Therapeutic approaches targeting intestinal microflora in inflammatory bowel disease. World J. Gastroenterol. 12, 44524460 (2006).
63. O’Mahony, L. et al. Probiotic impact on microbial flora, inflammation and tumour development in IL10 knockout mice. Aliment. Pharmacol. Ther. 15, 12191225 (2001).
64. Singh, J. et al. Bifidobacterium longum, a lactic acidproducing intestinal bacterium inhibits colon cancer and modulates the intermediate biomarkers of colon carcinogenesis. Carcinogenesis 18, 833841 (1997).
65. Dobbs, R. J. et al. Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 1: eradication of Helicobacter in the cachexia of idiopathic parkinsonism. Helicobacter 10, 267275 (2005).
66. Bjarnason, I. T. et al. Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 2: response of facets of clinical idiopathic parkinsonism to Helicobacter pylori eradication. A randomized, double-blind, placebo-controlled efficacy
study. Helicobacter 10, 276287 (2005).
67. Weller, C. et al. Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 3: predicted probability and gradients of severity of idiopathic parkinsonism based on H. pylori antibody profile. Helicobacter 10, 288297 (2005).

키워드

장내미생물,   신약개발,   미생물,   microbiome,   gut microbiota,   microbiota,   인체내미생물,   마이크로바이옴